Estimated COVID-19 Cases and Hospitalizations Averted by Case Investigation and Contact Tracing in the US.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 03 2022
Historique:
entrez: 25 3 2022
pubmed: 26 3 2022
medline: 2 4 2022
Statut: epublish

Résumé

Evidence of the impact of COVID-19 case investigation and contact tracing (CICT) programs is lacking, but policy makers need this evidence to assess the value of such programs. To estimate COVID-19 cases and hospitalizations averted nationwide by US states' CICT programs. This decision analytical model study used combined data from US CICT programs (eg, proportion of cases interviewed, contacts notified or monitored, and days to case and contact notification) with incidence data to model outcomes of CICT over a 60-day period (November 25, 2020, to January 23, 2021). The study estimated a range of outcomes by varying assumed compliance with isolation and quarantine recommendations. Fifty-nine state and territorial health departments that received federal funding supporting COVID-19 pandemic response activities were eligible for inclusion. Data analysis was performed from July to September 2021. Public health case investigation and contact tracing. The primary outcomes were numbers of cases and hospitalizations averted and the percentage of cases averted among cases not prevented by vaccination and other nonpharmaceutical interventions. In total, 22 states and 1 territory reported all measures necessary for the analysis. These 23 jurisdictions covered 42.5% of the US population (approximately 140 million persons), spanned all 4 US Census regions, and reported data that reflected all 59 federally funded CICT programs. This study estimated that 1.11 million cases and 27 231 hospitalizations were averted by CICT programs under a scenario where 80% of interviewed cases and monitored contacts and 30% of notified contacts fully complied with isolation and quarantine guidance, eliminating their contributions to future transmission. As many as 1.36 million cases and 33 527 hospitalizations could have been prevented if all interviewed cases and monitored contacts had entered into and fully complied with isolation and quarantine guidelines upon being interviewed or notified. Across both scenarios and all jurisdictions, CICT averted an estimated median of 21.2% (range, 1.3%-65.8%) of the cases not prevented by vaccination and other nonpharmaceutical interventions. These findings suggest that CICT programs likely had a substantial role in curtailing the pandemic in most jurisdictions during the 2020 to 2021 winter peak. Differences in outcomes across jurisdictions indicate an opportunity to further improve CICT effectiveness. These estimates demonstrate the potential benefits from sustaining and improving these programs.

Identifiants

pubmed: 35333362
pii: 2790518
doi: 10.1001/jamanetworkopen.2022.4042
pmc: PMC8956978
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e224042

Références

Open Forum Infect Dis. 2021 Jul 01;8(7):ofab304
pubmed: 34258323
Nature. 2020 Dec;588(7838):384-387
pubmed: 33318682
J Gen Intern Med. 2020 Aug;35(8):2296-2303
pubmed: 32472486
J Public Health Manag Pract. 2022 Jan-Feb 01;28(1):16-24
pubmed: 34534993
JAMA Netw Open. 2021 Jun 1;4(6):e2115850
pubmed: 34081135
BMJ. 2021 Mar 31;372:n608
pubmed: 33789843
Value Health. 2013 Mar-Apr;16(2):231-50
pubmed: 23538175

Auteurs

Gabriel Rainisch (G)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.

Seonghye Jeon (S)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.

Danielle Pappas (D)

Epidemiology and Laboratory Capacity Program, Centers for Disease Control and Prevention, Atlanta, Georgia.

Kimberly D Spencer (KD)

Epidemiology and Laboratory Capacity Program, Centers for Disease Control and Prevention, Atlanta, Georgia.

Leah S Fischer (LS)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.

Bishwa B Adhikari (BB)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.

Melanie M Taylor (MM)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.

Bradford Greening (B)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.

Patrick K Moonan (PK)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.

John E Oeltmann (JE)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.

Emily B Kahn (EB)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.

Michael L Washington (ML)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.

Martin I Meltzer (MI)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH